Recursion Pharmaceuticals is using AI to improve clinical trial design, patient enrollment and evidence generation as it prepares to advance seven programs to human trials or data readouts this year. "We want to be first in class, best in class, and best in industry -- not just using AI in discovery, but also in development," says Najat Khan, chief research and development officer and chief commercial officer.